Doctor: ‘We have been preparing for this moment for a very long time’ | DW New

Key Concepts

• CPS-1 Deficiency: A rare genetic disease where infants lack an enzyme to remove ammonia, leading to toxic buildup.
• CRISPR Gene Editing: A technology used to precisely edit DNA sequences, offering potential cures for genetic diseases.
• Bespoke Therapy: A treatment tailored to an individual patient's specific genetic mutation.
• Somatic Gene Editing: Editing genes in body cells that are not passed on to future generations, ethically less controversial than germline editing.
• Platform Path: A streamlined process developed through the successful treatment of KJ, enabling faster, cheaper, and more scalable development of similar therapies.

KJ's Case: A Breakthrough in Gene Editing

KJ Mulun, diagnosed with severe CPS-1 deficiency shortly after birth, received an experimental, tailor-made gene editing treatment. This condition, affecting approximately one in a million babies, prevents the body from removing ammonia, leading to toxic levels. Fedor Ornov of UC Berkeley's Innovative Genomics Institute, deeply involved in the process, described the moment of breakthrough as hearing from Dr. Rence Nicholas that the first injection went well and KJ started to have protein again. The success was not guaranteed, but the collaborative effort of multiple organizations made it possible.

The Collaborative Effort

The success of KJ's treatment was attributed to a "fellowship of a crisper cure," involving multiple individuals and organizations with specialized expertise:

• Dr. Rence Nicholas (CHOP): Expertise in caring for children with CPS-1 deficiency.
• Dr. Kiran Musunuru (Pen Medicine): Led the effort to create the CRISPR.
• Innovative Genomics Institute (UC Berkeley, founded by Jennifer Doudna): Conducted specificity assessment.
• Integrated DNA Technologies and Aldevron: Specialized in manufacturing clinical-grade CRISPR.
• Jackson Labs: Created a special mouse model with KJ's specific mutation.

This parallel work, driven by the urgency highlighted by Dr. Nicholas that waiting until KJ was 8 or 9 months old would be too late, was crucial.

Significance of the Breakthrough

Ornov emphasized that while creating a CRISPR gene editor is relatively common, producing one of sufficient quality for FDA approval and injection into a living baby is a significant achievement. Jennifer Doudna's vision for CRISPR as a genetic medicine for everyone who needs it is now closer to reality. Ornov stated that "for the first time since this technology was invented we can seriously look parents in the eye who have children living with these diseases and say we have entered a fundamentally new chapter in biio medicine."

Applicability to Other Genetic Mutations

The beauty of CRISPR lies in its adaptability. The principles are relatively simple: CRISPR can be programmed to repair one mutation and then easily changed to address another. Ornov stated that "we have never had a medicine where relatively simple principles can let you go from person one with mutation one to person two with mutation two."

The "Platform Path"

A key outcome of KJ's case is the establishment of a "platform path" – a new partnership between academia, industry, and the FDA. This streamlined process, developed through the successful treatment of KJ, enables faster, cheaper, and more scalable development of similar therapies. The success with KJ serves as a proof of concept.

Ethical Considerations and Scalability

Julian Kunovad from the Technical University of Munich highlighted that this case demonstrates the feasibility of developing customized gene editing therapies for individual patients with unique mutations using CRISPR 2.0. While gene editing therapies are already in clinical trials and one CRISPR therapy is on the market, the ability to create bespoke treatments is a significant advancement.

Kunovad emphasized that the major challenge is scaling this approach to benefit more families, requiring infrastructure, production capabilities, and a regulatory framework. Safety remains paramount.

Ethically, the treatment of KJ involves somatic gene editing, which is less controversial than germline editing (editing genes passed to future generations). The primary ethical concern is accessibility and equity, as these therapies are currently very expensive.

Conclusion

KJ's successful treatment represents a major milestone in gene editing, demonstrating the potential of CRISPR technology to treat rare genetic diseases with bespoke therapies. The collaborative effort and the establishment of a "platform path" pave the way for faster, cheaper, and more scalable development of similar treatments. While ethical considerations and scalability challenges remain, this breakthrough offers hope for families affected by genetic disorders.